Men with newly diagnosed metastatic hormone-sensitive prostate cancer now have a new treatment combination that offers survival benefits unparalleled to that seen in other trials in this disease setting. At the ASCO plenary session, the results of a randomized phase III trial in which men were randomly assigned to androgen-deprivation therapy (ADT) alone or ADT plus docetaxel were presented. Median overall survival was 57.6 months in the combination arm and 44.0 months in the hormonal therapy arm. The overall survival difference between the two arms was even greater in men with high-volume disease (49.2 months versus 32.2 months). For men with low-volume disease, median overall survival had not been reached at the time of analysis. These data point to a new standard of care for hormone-sensitive tumours, certainly in men with high-volume disease.
References
Sweeney, C. et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly diagnosed metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial [abstract]. ASCO Annual Meeting 2014 LBA2 (2014)
Rights and permissions
About this article
Cite this article
Chemohormonal therapy leads the way in prostate cancer. Nat Rev Clin Oncol 11, 380 (2014). https://doi.org/10.1038/nrclinonc.2014.106
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.106
This article is cited by
-
Integrating Bone Targeting Radiopharmaceuticals Into the Management of Patients With Castrate-Resistant Prostate Cancer With Symptomatic Bone Metastases
Current Treatment Options in Oncology (2015)
